News
Cipla, Takeda to commercialise Vonoprazan drug in India
IMT News Desk
Cipla, Takeda to commercialise Vonoprazan drug in India
IMT News Desk
The deal is meant to commercialise the drug in India under Cipla’s trademark brands
Cipla has signed a non-exclusive Patent License agreement with Takeda Pharmaceutical Company for ‘Vonoprazan’ for the India Market for treating acid-related illnesses among patients. The deal is meant to commercialise the drug in India under Cipla’s trademark brands.
Vonoprozan (oral tablets) is a novel potassium-competitive acid blocker (P-CAB), used for the treatment of related disorders - Gastroesophageal Reflux Disease (GERD). Vonoprozan will help in treating disorders such as erosive oesophagitis, gastric ulcer, duodenal ulcer, peptic ulcer, gastro-oesophageal reflux, reflux oesophagitis and Helicobacter pylori eradication.
Achin Gupta, CEO – One India Business, Cipla, said, “Bringing new and advanced therapies to the Indian market has always been a key area of focus for us. We believe this partnership will not only address a significant medical need but also strive to provide a better quality of life for patients.”